Plasma protein binding probe (for vascular imaging) (null)

This imaging approach exploits the natural distribution and high abundance of plasma proteins (primarily albumin, also transthyretin) to enhance visualization of vascular architecture and permeability using labeled probes that bind plasma proteins. These probes circulate for extended periods, accumulating in tissues with abnormal vasculature such as tumors or inflamed regions, and can be detected by imaging modalities like PET, SPECT, or MRI. While extremely useful for characterizing vascular pathology and guiding drug development, "plasma protein binding" is a mechanism rather than a discrete molecular target, with no singular receptor or binding site; imaging agents are designed to interact reversibly or covalently with plasma proteins, leveraging their transport and distribution characteristics.

Other names

Albumin-binding probeplasma protein-binding radioligandHSA-binding agent

Drugs/pictures bind plasma proteins (mainly albumin or transthyretin), prolong circulation, accumulate in regions with altered vascular permeability, enabling imaging or improving drug delivery